David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.09% |
| 2 | Technology | 17.04% |
| 3 | Healthcare | 13.44% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Financials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Cracker Barrel
CBRL
$1.25B
| $2.21M | ﹤0.01% |
13,662
+4,182
| +44% | +$688K |
|
2052
TG Therapeutics
TGTX
$8.41B
| $2.2M | ﹤0.01% |
273,567
+200,553
| +275% | +$1.08M |
|
2053
Jack in the Box
JACK
$308M
| $2.19M | ﹤0.01% |
27,041
-90,597
| -77% | -$7.25M |
|
2054
PUT
HSBC
HSBC
$352B
| $2.19M | ﹤0.01% |
54,643
+28,713
| +111% | +$1.16M |
|
2055
MarketAxess Holdings
MKTX
$5.72B
| $2.19M | ﹤0.01% |
8,900
+1,399
| +19% | +$317K |
|
2056
CALL
Public Storage
PSA
$58.9B
| $2.18M | ﹤0.01% |
+10,000
| New | +$2.09M |
|
2057
FormFactor
FORM
$8.64B
| $2.18M | ﹤0.01% |
135,300
-14,672
| -10% | -$221K |
|
2058
Manulife Financial
MFC
$71.6B
| $2.18M | ﹤0.01% |
128,542
-611,855
| -83% | -$9.95M |
|
2059
PUT
MKS Inc
MKSI
$18.3B
| $2.18M | ﹤0.01% |
23,400
-800
| -3% | -$64.5K |
|
2060
BCE
BCE
$21.9B
| $2.18M | ﹤0.01% |
49,015
-633,041
| -93% | -$27.3M |
|
2061
CALL
Darden Restaurants
DRI
$24.3B
| $2.17M | ﹤0.01% |
17,900
-50,400
| -74% | -$5.53M |
|
2062
PUT
AutoNation
AN
$6.55B
| $2.17M | ﹤0.01% |
60,800
+45,000
| +285% | +$1.63M |
|
2063
PUT
Ichor Holdings
ICHR
$2.2B
| $2.17M | ﹤0.01% |
95,900
-75,600
| -44% | -$1.54M |
|
2064
LivaNova
LIVN
$4.39B
| $2.17M | ﹤0.01% |
22,264
-18,258
| -45% | -$1.7M |
|
2065
Omnicell
OMCL
$1.53B
| $2.16M | ﹤0.01% |
+26,766
| New | +$2M |
|
2066
PUT
Novartis
NVS
$294B
| $2.16M | ﹤0.01% |
25,110
| – | – |
|
2067
Helios Technologies
HLIO
$2.47B
| $2.16M | ﹤0.01% |
+46,441
| New | +$1.86M |
|
|
ONDK
2068
DELISTED
On Deck Capital, Inc.
ONDK
| $2.16M | ﹤0.01% |
398,310
-117,851
| -23% | -$747K |
|
2069
Paychex
PAYX
$45.1B
| $2.16M | ﹤0.01% |
26,908
+6,199
| +30% | +$457K |
|
|
PGRE
2070
DELISTED
Paramount Group
PGRE
| $2.15M | ﹤0.01% |
151,809
-485,962
| -76% | -$6.85M |
|
2071
PUT
First Solar
FSLR
$22.7B
| $2.15M | ﹤0.01% |
40,700
-15,600
| -28% | -$785K |
|
|
BEDU
2072
DELISTED
Bright Scholar Education Holdings
BEDU
| $2.15M | ﹤0.01% |
51,949
+36,618
| +239% | +$1.57M |
|
|
WCN
2073
Waste Connections
WCN
$41.6B
| $2.15M | ﹤0.01% |
24,232
-2,852
| -11% | -$235K |
|
|
OSG
2074
DELISTED
Overseas Shipholding Group Inc.
OSG
| $2.15M | ﹤0.01% |
938,300
+124,768
| +15% | +$249K |
|
2075
PUT
Olin
OLN
$1.97B
| $2.15M | ﹤0.01% |
92,800
-64,000
| -41% | -$1.53M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.